LTR PHARMA LIMITED ORDINARY (LTP) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXLTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
other announcement
LTR Secures First U.S. Commercial Agreement for ROXUS
other announcement
SPONTAN Phase II data show rapid onset, support FDA pathway
other announcement
SPONTAN Phase II Clinical Study Completes Recruitment
other announcement
SPONTAN Shows Positive Outcomes in Younger Men with ED
other announcement
First Patients Dosed in SPONTAN Phase II Clinical Study
other announcement
Patient Recruitment Commences for SPONTAN Phase II Study
other announcement
SPONTAN Phase 1 Study Accepted for WMSM 2026 Podium
other announcement
TGA Provides Regulatory Clearance for SPONTAN Phase II
other announcement
Ethics Approval Received for SPONTAN Phase II Clinical Study
other announcement
Release of Restricted Securities from ASX Mandatory Escrow
other announcement
Change of Director's Interest Notice - M McGuire
director_dealing announcement
Change of Director's Interest Notice - J Chick
director_dealing announcement
Change of Director's Interest Notice - L Rodne
director_dealing announcement
LTR increases LevOmega stake to 43% with $1m investment
other announcement
LTR Pharma secures 33% ownership in LevOmega Pty Ltd
other announcement
SPONTAN Case Series - Strong Post-Prostatectomy Results
other announcement
18-Month Shelf Life Strengthens SPONTAN Commercialisation
other announcement
US ED Specialist Dr Pearlman Joins LTR Advisory Board
other announcement
LTP Completes Extractables Study Milestone for SPONTAN
other announcement
Urological Expert Appointed to LTR Scientific Advisory Board
other announcement
SPONTAN Expands Patient Access via National Pharmacy Network
other announcement
LTR Signs Collaborative Agreement to Develop OMD Nasal Spray
other announcement
LTR Pharma to Showcase SPONTAN Data at Urology Conference
other announcement